Beta
Trial Radar KI
Die klinische Studie NCT06921486 für Obesity and Overweight ist aktiv, nicht rekrutierend. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen.
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT) Phase 2, Phase 3 1.003 Randomisiert Doppelblind Placebo-kontrolliert

Aktiv, nicht rekrutierend
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT06921486 untersucht Behandlung im Zusammenhang mit Obesity and Overweight. Diese interventionsstudie der Phase 2 Phase 3 hat den Status aktiv, nicht rekrutierend und startete am 31. März 2025. Es ist geplant, 1.003 Teilnehmer aufzunehmen. Durchgeführt von Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. wird der Abschluss für 31. Dezember 2026 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 30. Januar 2026 aktualisiert.
Kurzbeschreibung
This study is a multicenter, randomized, double-blind, placebo-controlled Phase IIb/III clinical trial aimed at evaluating the efficacy, safety, pharmacokinetics (PK), and immunogenicity profile of Efsubaglutide Alfa injection in overweight and obese subjects. The primary endpoint of the Phase IIb is the percentage change in body weight from baseline after 18 weeks of treatment. The primary endpoint of the Phase III ...Mehr anzeigen
Offizieller Titel

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb/III Clinical Trial to Evaluate the Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects

Erkrankungen
Obesity and Overweight
Weitere Studien-IDs
  • YN011-W303
  • YN011-W202 (Andere Kennung) (Guangzhou Innogen Pharmaceutical Group Co., Ltd.)
  • YN011-W303 (Andere Kennung) (Guangzhou Innogen Pharmaceutical Group Co., Ltd.)
NCT-Nummer
NCT06921486
Studienbeginn (tatsächlich)
2025-03-31
Zuletzt aktualisiert
2026-01-30
Studienende (vorauss.)
2026-12-31
Geplante Rekrutierung
1.003
Studientyp
Interventionsstudie
PHASE
Phase 2
Phase 3
Status
Aktiv, nicht rekrutierend
Primäres Ziel
Behandlung
Zuteilungsmethode
Randomisiert
Interventionsmodell
Parallel
Verblindung
Vierfach verblindet
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
ExperimentellPhase IIb：Efsubaglutide Alfa 5 mg QW
The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg, reaching the target dose of 5 mg at Week 3 (W3). From W3 to W18, the treatment is maintained at a 5 mg dose.
Phase IIb：Efsubaglutide Alfa 5 mg QW
IIb：Efsubaglutide Alfa 5 mg QW
ExperimentellPhase IIb：Efsubaglutide Alfa 10 mg QW
The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg, reaching the target dose of 10 mg at Week 5 (W5). From W5 to W18, the treatment is maintained at a 10 mg dose.
Phase IIb：Efsubaglutide Alfa 10 mg QW
Efsubaglutide Alfa 10 mg QW
ExperimentellPhase IIb：Efsubaglutide Alfa 20 mg QW
The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 mg, reaching the target dose of 20 mg at Week 7 (W7). From W7 to W18, the treatment is maintained at a 20 mg dose.
Phase IIb：Efsubaglutide Alfa 20 mg QW
Efsubaglutide Alfa 20 mg QW
ExperimentellPhase IIb：Efsubaglutide Alfa 20 mg Q2W
From Week 1 (W1) to Week 6 (W6), the drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 mg, reaching the target dose of 20 mg at Week 7 (W7). From W7 to W18, the drug is administered every two weeks and maintained at a 20 mg dose.
Phase IIb：Efsubaglutide Alfa 20 mg Q2W
Efsubaglutide Alfa 20 mg Q2W
Placebo-VergleichspräparatPhase IIb：Placebo
Once weekly
Phase IIb：Placebo
Placebo
ExperimentellPhase III：Recommended Phase 3 Dose (RP3D) Low Dose QW
The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 mg, The dose escalation continues until reaching the RP3D Low Dose, and then the RP3D is maintained. The total cumulative duration of drug administration (from the first dose to the end of maintenance) is 48 weeks, with the once-weekly administration frequency...Mehr anzeigen
Phase III：Recommended Phase 3 Dose Low Dose
The Recommended Phase 3 Dose Low Dose confirmed by the IDMC (Independent Data Monitoring Committee) based on the safety and efficacy data results from the 18-week Phase IIb.
ExperimentellPhase III：Recommended Phase 3 Dose (RP3D) High Dose QW
The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 mg, The dose escalation continues until reaching the RP3D High Dose, and then the RP3D is maintained. The total cumulative duration of drug administration (from the first dose to the end of maintenance) is 48 weeks, with the once-weekly administration frequenc...Mehr anzeigen
Phase III：Recommended Phase 3 Dose High Dose
The Recommended Phase 3 Dose High Dose confirmed by the IDMC (Independent Data Monitoring Committee) based on the safety and efficacy data results from the 18-week Phase IIb.
ExperimentellPhase III：Recommended Phase 3 Dose (RP3D) High Dose Q2W
The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence: 1 mg → 5 mg → 10 mg → 20 mg. Dose escalation continues until reaching the RP3D High Dose. Once the RP3D High Dose is achieved, the treatment regimen transitions to alternating weekly between RP3D High Dose and placebo for the remainder of the study. The total cumulative duration of drug...Mehr anzeigen
Phase III：Recommended Phase 3 Dose High Dose
The Recommended Phase 3 Dose High Dose confirmed by the IDMC (Independent Data Monitoring Committee) based on the safety and efficacy data results from the 18-week Phase IIb.
Phase III：Placebo
Placebo
Placebo-VergleichspräparatPhase III：Placebo
Once weekly
Phase III：Placebo
Placebo
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Percentage change in body weight from baseline
Phase IIb (18 weeks) , Phase III (30 weeks)
Proportion of subjects with ≥5% reduction in body weight from baseline
Phase III (30 weeks)
Nebenergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Proportion of subjects with ≥5% reduction in body weight from baseline
Phase IIb (18 weeks) , Phase III (48 weeks)
Proportion of subjects with ≥10%, and ≥15% reduction in body weight from baseline
Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)
Percentage change in body weight from baseline
Phase III (48 weeks)
Change in body weight from baseline
Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)
Change in BMI from baseline
Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)
Change in waist circumference from baseline
Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)
Change in hip circumference from baseline
Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)
Change in blood pressure (diastolic and systolic) from baseline
Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)
Change in lipid levels (triglycerides, total cholesterol, low-density lipoprotein cholesterol) from baseline, percentage change from baseline, and ratio to baseline.
Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)
Change in blood glucose levels (FPG) from baseline
Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)
Change in blood glucose levels (HbA1c) from baseline
Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)
Change in blood glucose levels (fasting insulin) from baseline
Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)
Change in blood glucose levels (insulin resistance index [HOMA-IR]) from baseline
Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)
Change in blood uric acid levels from baseline
Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)
Change in IWQOL-lite-CT (Impact of Weight on Quality of Life-Lite-Clinical Trial Version) Questionnaire Score from Baseline
Phase III (30 weeks and 48 weeks)
Teilnahme-Assistent
Eignungskriterien

Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Alle
  1. Voluntarily participate in the clinical study; fully understand and be informed about the study, and sign the informed consent form (ICF); willing to follow and capable of completing all study procedures.
  2. Age ≥ 18 years (including the cutoff value, based on the time of signing the ICF), regardless of gender.
  3. History of poor weight control through diet and exercise \[defined as weight control failure if the subject has attempted at least 3 months of diet and exercise alone prior to screening without achieving a weight loss of ≥ 5.0% (based on subject self-report)\].
  4. Willing to follow the recommendations of the investigator regarding medication, diet, and exercise.
  5. Stable weight within 3 months prior to screening (defined as a weight change < 5%, based on subject self-report).
  6. Obesity: Body Mass Index (BMI) ≥ 28 kg/m² (including the cutoff value) with or without comorbidities; or overweight: BMI ≥ 24 and < 28 kg/m² with at least one weight-related comorbidity, including but not limited to prediabetes (impaired fasting glucose \[FPG\] and/or abnormal glucose tolerance), hypertension, dyslipidemia, non-alcoholic fatty liver disease, or obstructive sleep apnea syndrome.
  7. Women of childbearing potential must have a negative blood pregnancy test during the screening period. Women of childbearing potential or male subjects and their partners must agree not to plan for pregnancy from the time of signing the ICF until 3 months after the last dose of the investigational drug, and voluntarily agree to use effective contraception, with no plans for sperm or egg donation.

  1. Allergic constitution or allergic to any component of the investigational drug.
  2. Previously treated with Efsubaglutide Alfa injection.
  3. Received glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, insulin, metformin, insulin secretagogues, or thiazolidinediones (TZD) or any other weight-affecting anti-diabetic medication within the past 3 months before screening.
  4. HbA1c ≥ 6.5% at screening, or previously diagnosed with Type 1 or Type 2 diabetes (based on the World Health Organization \[WHO\] 2020 diabetes diagnosis and classification standards).
  5. History of severe hypoglycemia or recurrent symptomatic hypoglycemia (≥ 2 times in the past 6 months).
  6. Known single-gene mutations, other diseases, or drug-induced obesity, including but not limited to hypothalamic obesity, pituitary obesity, hypothyroid obesity, Cushing's syndrome, insulinoma, growth hormone deficiency, acromegaly, pseudohypoparathyroidism, gonadal dysfunction, etc.
  7. Clinically significant gastric emptying abnormalities (e.g., gastric outlet obstruction), severe chronic gastrointestinal diseases (e.g., active ulcers in the past 6 months), long-term use of drugs directly affecting gastrointestinal motility (including but not limited to mosapride, cisapride, etc.), or having undergone gastrointestinal surgery within the past 6 months and deemed unsuitable for participation by the investigator.
  8. Use of weight-affecting medications within 3 months prior to screening, including tricyclic antidepressants, psychiatric medications, or sedative drugs (such as imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, sulpiride, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts, etc.). Note: Excluded if cumulative or continuous systemic steroid use is less than 14 days.
  9. Use of non-prescription weight loss medications or appetite suppressants (including traditional Chinese medicine weight loss drugs) within 1 month prior to screening, or use of prescription weight loss medications (e.g., phentermine, sibutramine, orlistat) or lipid-dissolving injectables (e.g., lipolytic injections) within 3 months prior to screening.
  10. Previously underwent weight-loss surgery (excluding acupuncture, liposuction, and abdominal fat removal within 1 year before screening), or plans to undergo surgery for obesity during the study period, such as gastric bypass surgery or gastric band surgery.
  11. Currently on a weight loss plan and not in the maintenance phase.
  12. History of hyperthyroidism or hypothyroidism, or thyroid-stimulating hormone (TSH) < 1×LLN (lower limit of normal) or TSH > 1.5×ULN (upper limit of normal).
  13. Screening serum calcitonin ≥ 50 ng/L (or ≥ 50 pg/mL), or history of medullary thyroid cancer, multiple endocrine neoplasia (MEN) syndrome type 2A or 2B, or related family history (family history defined as a first-degree relative with the disease).
  14. History of acute or chronic pancreatitis, cholecystectomy, or symptomatic gallbladder disease (patients with post-surgery resolved gallstones or cholecystectomy without sequelae can be enrolled), or known history of pancreatic injury or high-risk factors for pancreatitis, or screening with serum amylase or lipase > 2×ULN.
  15. Any disease that could affect HbA1c measurement, such as hemolytic anemia, sickle cell disease, etc.
  16. Currently receiving or have received chronic (> 14 days) systemic corticosteroid treatment in the past 3 months (excluding local, intraocular, intranasal, intra-articular, or inhaled formulations), or have evidence of severe, active autoimmune disorders (e.g., lupus or rheumatoid arthritis), and, in the opinion of the investigator, require or may require systemic corticosteroid treatment within the next 12 months.
  17. History of malignancy within 5 years prior to screening, excluding clinically cured cervical carcinoma in situ, squamous cell carcinoma of the skin, or basal cell carcinoma within the past 5 years.
  18. History of major surgery (e.g., thoracic, intracranial, or abdominal surgery) within 6 months prior to screening, or plans to undergo surgery that may affect study completion or adherence.
  19. Meets any of the following cardiac function criteria: clinically significant arrhythmias or conduction abnormalities requiring clinical intervention; hereditary long QT syndrome or QTcF > 450 msec or currently taking medications that may prolong the QT interval or cause torsades de pointes; clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, coronary artery bypass graft surgery, New York Heart Association (NYHA) class III or higher congestive heart failure, left ventricular ejection fraction (LVEF) < 50%, or uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg); other clinically significant cardiac abnormalities judged by the investigator.
  20. History of hemorrhagic or ischemic stroke or transient ischemic attack within 6 months prior to screening.
  21. Known infectious diseases: hepatitis B surface antigen (HBsAg) positive; hepatitis C virus (HCV) antibody positive and HCV RNA above the detection limit; human immunodeficiency virus (HIV) antibody positive; Treponema pallidum antibody positive.
  22. Laboratory findings meeting any of the following: alanine aminotransferase (ALT) ≥ 3.0×ULN (subjects diagnosed with non-alcoholic fatty liver disease during screening and within the past 6 months with ALT ≤ 5.0×ULN may be enrolled); aspartate aminotransferase (AST) ≥ 3.0×ULN; total bilirubin (TBIL) ≥ 2.0×ULN; estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m² (CKD-EPI formula); fasting triglycerides (TG) > 5.65 mmol/L.
  23. Known or suspected alcohol abuse within 1 year prior to screening (defined as male subjects consuming > 24 g alcohol per day, female subjects consuming > 12 g alcohol per day; 12 g alcohol is approximately equivalent to 300 mL beer, 100 mL wine, or 25 mL spirits).
  24. Known or suspected drug abuse at screening.
  25. Pregnant or breastfeeding women.
  26. History of moderate to severe depression, anxiety, or serious mental disorders, such as schizophrenia, bipolar disorder, etc., or screening PHQ-9 score ≥ 15.
  27. History of suicidal tendencies or suicide attempts.
  28. Participation in a clinical trial involving vaccines, medical devices, or other drugs within 3 months prior to screening (except for observational studies).
  29. The investigator or treating physician considers that the subject has any factors that may affect the evaluation of the efficacy or safety of the study, and is deemed unsuitable for participation in the study.
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. logoShanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Keine Kontaktdaten vorhanden
41 Studienstandorte in 1 Ländern
Beijing Friendship Hospital, Capital Medical University, Beijing, China
Beijing Tsinghua Changgung Hospital, Beijing, China
Peking University First Hospital, Beijing, China
Changzhou First People's Hospital, Changzhou, China
Sichuan Academy of Medical Sciences &Sichuan Provincial People's Hospital, Chengdu, China
Nanfang Hospital Southern Medical University, Guangzhou, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
The First Affiliateo Hospital of Jinan University, Guangzhou, China
Zhujiang Hospital of Southern Medical University, Guangzhusi, China
The First People'S Hospital of Zunyi, Guizhou, China
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
Anhui Provincial Hospital, Hefei, China
The First Affiliated Hospital of Henan University of Science and Technology, Henan, China
The First Affiliated Hospital of Nanyang Medical College, Henan, China
Pingxiang People's Hospital, Jiangxi, China
Jincheng General Hospital, Jincheng, China
The Third Affiliated Hospital, Jinzhou, China
The First People's Hospital of Yunnan Province, Kunming, China
Luan City People's Hospital, Lu'an, China
Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, China
Nan Jing First Hospital, Nanjing, China
The Second Hospital of Nanjing Medical University, Nanjing, China
The Affiliated Qingyuan Hospital ,Guangzhou Medical University（Qingyuan People's Hospital）, Qingyuan, China
The First Hospital of Qinhuangdao, Qinhuangdao, China
Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong, China
Shanghai Sixth People's Hospital Affiliated to Shanghai JiaoTong University, Shanghai, 200030, China
Shanghai General Hospital, Shanghai, China
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
The First Hospital Of China Medical University, Shenyang, China
Shenzhen Second People's Hospital, Shenzhen, China
The First Hospital of Hebei Medical University, Shijiazhuang, China
The Second Hospital of Hebei Medical University, Shijiazhuang, China
Suzhou Municipal Hospital, Suzhou, China
The Second Affiliated Hospital of Soochow University, Suzhou, China
General Hospital of Tianjin Medical University, Tianjin, China
Tianjin Medical University Chu Hsien-I Memorial Hospital, Tianjin, China
Tenth People's Hospital Of Tongji University, Wuhan, China
Wuhan Third Hospital Tongren Hospital of Wuhan University, Wuhan, China
The First Affiliated Hospital of Xi'an Jiao Tong University, Xianian, China
Yueyang Central Hospital, Yueyang, China